Gérald Ulrich

CEVA Santé Animale SA develops and manufactures animal health products. It offers parasiticides, metabolism correctors, and pharmaceutical products for companion animals, ruminants, swine, and poultry. The company was founded in 1999 and is headquartered in Libourne, France.

Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.

Vauban Partenaires SA (VP) is an independent boutique-sized private equity firm established in 1992 and based in Paris. Crédit Agricole SA (XP: ACA) is a significant minority shareholder. The firm operates in close relationship with their majority-owned subsidiary Participex Gestion, based in Lille in northern France. Both firms manage private equity funds including regional development funds. Their clients are leading financial institutions, regional banks and insurance companies. Their lead investors are regional subsidiaries of Crédit Agricole.

Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France.

FA Dièse SAS is the Paris office of FA Dièse, a French private equity investment firm established in Bordeaux in 2001. The firm started operating in Paris in 2007. The shareholders of FA Dièse include business angels and entrepreneurs, as well as institutions such as banks, insurance companies and regional private equity funds.

Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process . The firm's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients. Founded in 2000, Gene Signal has assembled an strong leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline.

Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland.

Société Petroliere du Bec d'Ambes provides refrigerated storage facility services. The company is headquartered in Carbon-Blanc, France.

Astra Zeneca Holding France SAS operates as a holding firm with interest in pharmaceuticals. The company was founded in 1994 and is headquartered in Rueil-Malmaison, France.

BASF France manufactures and markets coating products. The company is headquartered in Levallois-Perret, France.

Medtronic France SAS provides medical equipment and medical technology services. The company was founded by Earl Bakken and Palmer Hermundslie in 1949 and is headquartered in Boulogne-Billancourt, France.

Microgen Bioproducts Ltd. develops, manufactures, distributes, and markets clinical laboratory products. It offers biochemical identification and latex agglutination kits, path-check hygiene and pregnancy tests, pulsifier, and bacterial typing antisera. The company was founded in 1994 and is headquartered in Camberley, the United Kingdom.

Laboratoires C.T.R.S. SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Boulogne-Billancourt, France. The company was founded in 2002 by Bernard Deschamps. The CEO is Antoine Ferry.

Love Hemp Group Plc operates as an investment vehicle, which identifies investment opportunities and acquisitions in companies. Its investment strategy is to focus on making investments and to acquire companies operating within the burgeoning legal medicinal cannabis, hemp and cannabidiol industries. The company was founded by David Alexander Stadnyk on January 30, 2019 and is headquartered in London, the United Kingdom.

Part of Novacyt SAS, Novacyt UK Holdings Ltd. is a diagnostics company that develops tests that detect infections. The company is based in Eastleigh, UK. The British company was founded in 2019. The CEO is James Martin Mccarthy.